Header Logo

Connection

Alan Go to Atrial Fibrillation

Back to Details
This is a "connection" page, showing publications Alan Go has written about Atrial Fibrillation.
Alan Go
Connection Strength
19.543
Atrial Fibrillation
  1. Incident Atrial Fibrillation and Risk of Dementia in a Diverse, Community-Based Population. J Am Heart Assoc. 2023 03 21; 12(6):e028290.
    View in: PubMed
    Score: 0.776
  2. Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. Stroke. 2023 Mar; 54(3):e75-e85.
    View in: PubMed
    Score: 0.775
  3. Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop. Circulation. 2020 06 09; 141(23):1915-1926.
    View in: PubMed
    Score: 0.642
  4. Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications. Am J Cardiol. 2020 02 15; 125(4):553-561.
    View in: PubMed
    Score: 0.618
  5. Thromboprophylaxis for Patients with High-risk Atrial Fibrillation and Flutter Discharged from the Emergency Department. West J Emerg Med. 2018 Mar; 19(2):346-360.
    View in: PubMed
    Score: 0.546
  6. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. Ann Intern Med. 2017 Dec 19; 167(12):845-854.
    View in: PubMed
    Score: 0.537
  7. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol. 2015 Feb; 8(1):49-58.
    View in: PubMed
    Score: 0.437
  8. Incident atrial fibrillation and risk of death in adults with chronic kidney disease. J Am Heart Assoc. 2014 Oct 20; 3(5):e001303.
    View in: PubMed
    Score: 0.434
  9. Intersection of cardiovascular disease and kidney disease: atrial fibrillation. Curr Opin Nephrol Hypertens. 2014 May; 23(3):275-82.
    View in: PubMed
    Score: 0.420
  10. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013 Jun 21; 2(3):e000250.
    View in: PubMed
    Score: 0.396
  11. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013 Feb 05; 127(5):569-74.
    View in: PubMed
    Score: 0.383
  12. Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry. Stroke. 2012 Oct; 43(10):2788-90.
    View in: PubMed
    Score: 0.373
  13. CHA2DS2-VASc risk scheme: not ready for clinical use. Chest. 2010 Oct; 138(4):1020; author reply 1020-1.
    View in: PubMed
    Score: 0.328
  14. The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation. Arch Intern Med. 2009 Nov 23; 169(21):2032; author reply 2033.
    View in: PubMed
    Score: 0.309
  15. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009 Sep 01; 151(5):297-305.
    View in: PubMed
    Score: 0.304
  16. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes. 2009 Jul; 2(4):297-304.
    View in: PubMed
    Score: 0.299
  17. The ACTIVE pursuit of stroke prevention in patients with atrial fibrillation. N Engl J Med. 2009 May 14; 360(20):2127-9.
    View in: PubMed
    Score: 0.298
  18. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009 Mar 17; 119(10):1363-9.
    View in: PubMed
    Score: 0.294
  19. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008 Jun; 39(6):1901-10.
    View in: PubMed
    Score: 0.277
  20. Stroke prevention in atrial fibrillation: another step sideways. Lancet. 2008 Jan 26; 371(9609):278-80.
    View in: PubMed
    Score: 0.272
  21. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. CNS Drugs. 2008; 22(10):815-25.
    View in: PubMed
    Score: 0.271
  22. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005 Sep 20; 112(12):1687-91.
    View in: PubMed
    Score: 0.231
  23. Antithrombotic therapy for stroke prevention in atrial fibrillation. Prog Cardiovasc Dis. 2005 Sep-Oct; 48(2):108-24.
    View in: PubMed
    Score: 0.231
  24. Anticoagulants for stroke prevention in atrial fibrillation: what is the right rate and where do we go from here? Nat Clin Pract Cardiovasc Med. 2005 May; 2(5):226-7.
    View in: PubMed
    Score: 0.225
  25. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. Am J Geriatr Cardiol. 2005 Mar-Apr; 14(2):56-61.
    View in: PubMed
    Score: 0.223
  26. Economic implications of transesophageal echocardiography-guided cardioversion of atrial fibrillation. J Am Coll Cardiol. 2004 Apr 07; 43(7):1225-7.
    View in: PubMed
    Score: 0.209
  27. Efficacy of anticoagulation for stroke prevention and risk stratification in atrial fibrillation: translating trials into clinical practice. Am J Manag Care. 2004 Apr; 10(3 Suppl):S58-65.
    View in: PubMed
    Score: 0.209
  28. Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol. 2004 Feb 04; 43(3):429-35.
    View in: PubMed
    Score: 0.207
  29. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003 Nov 26; 290(20):2685-92.
    View in: PubMed
    Score: 0.204
  30. Gaps in guideline-recommended anticoagulation in patients with atrial fibrillation and elevated thromboembolic risk within an integrated healthcare delivery system. BMC Cardiovasc Disord. 2023 11 21; 23(1):578.
    View in: PubMed
    Score: 0.204
  31. Clinical decision support to Optimize Care of patients with Atrial Fibrillation or flutter in the Emergency department: protocol of a stepped-wedge cluster randomized pragmatic trial (O'CAF? trial). Trials. 2023 Mar 31; 24(1):246.
    View in: PubMed
    Score: 0.195
  32. Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Thromb Thrombolysis. 2003 Feb; 15(1):41-6.
    View in: PubMed
    Score: 0.193
  33. Transforming Atrial Fibrillation Research to Integrate Social Determinants of Health: A National Heart, Lung, and Blood Institute Workshop Report. JAMA Cardiol. 2023 Feb 01; 8(2):182-191.
    View in: PubMed
    Score: 0.193
  34. ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor. Am Heart J. 2022 07; 249:76-85.
    View in: PubMed
    Score: 0.183
  35. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 09; 285(18):2370-5.
    View in: PubMed
    Score: 0.171
  36. Antithrombotic therapy in atrial fibrillation. Clin Geriatr Med. 2001 Feb; 17(1):131-47.
    View in: PubMed
    Score: 0.168
  37. Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2021 06; 77(6):907-919.
    View in: PubMed
    Score: 0.166
  38. Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. Eur Heart J Qual Care Clin Outcomes. 2020 10 01; 6(4):263-272.
    View in: PubMed
    Score: 0.164
  39. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 2000 Jul 04; 102(1):11-3.
    View in: PubMed
    Score: 0.161
  40. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2020 08; 226:85-93.
    View in: PubMed
    Score: 0.159
  41. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999 Dec 21; 131(12):927-34.
    View in: PubMed
    Score: 0.155
  42. Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2019 12; 12(12):e007612.
    View in: PubMed
    Score: 0.155
  43. Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. Circulation. 2020 02 11; 141(6):482-492.
    View in: PubMed
    Score: 0.154
  44. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2019 11; 12(11):e006212.
    View in: PubMed
    Score: 0.154
  45. Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study. J Am Heart Assoc. 2019 08 06; 8(15):e012200.
    View in: PubMed
    Score: 0.151
  46. Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. Am Heart J. 2019 07; 213:81-90.
    View in: PubMed
    Score: 0.148
  47. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. J Thromb Thrombolysis. 2018 Nov; 46(4):435-439.
    View in: PubMed
    Score: 0.144
  48. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart. 2018 11; 104(22):1850-1858.
    View in: PubMed
    Score: 0.140
  49. Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). Circ Arrhythm Electrophysiol. 2017 Nov; 10(11).
    View in: PubMed
    Score: 0.134
  50. Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. J Am Coll Cardiol. 2017 Sep 12; 70(11):1325-1335.
    View in: PubMed
    Score: 0.133
  51. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes. 2017 07 01; 3(3):192-197.
    View in: PubMed
    Score: 0.131
  52. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clin Cardiol. 2017 Sep; 40(9):746-751.
    View in: PubMed
    Score: 0.130
  53. Health Literacy and Awareness of Atrial Fibrillation. J Am Heart Assoc. 2017 Apr 11; 6(4).
    View in: PubMed
    Score: 0.129
  54. Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke. J Am Geriatr Soc. 2017 Feb; 65(2):241-248.
    View in: PubMed
    Score: 0.126
  55. Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. J Am Geriatr Soc. 2017 01; 65(1):35-41.
    View in: PubMed
    Score: 0.125
  56. Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation. 2016 10 11; 134(15):1122-1124.
    View in: PubMed
    Score: 0.124
  57. Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. JAMA Cardiol. 2016 Aug 01; 1(5):548-56.
    View in: PubMed
    Score: 0.123
  58. Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Heart Assoc. 2016 07 22; 5(7).
    View in: PubMed
    Score: 0.123
  59. How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation? Am J Cardiol. 2016 09 01; 118(5):697-9.
    View in: PubMed
    Score: 0.122
  60. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circ Arrhythm Electrophysiol. 2016 06; 9(6).
    View in: PubMed
    Score: 0.121
  61. Atrial Fibrillation and Risk of ESRD in Adults with CKD. Clin J Am Soc Nephrol. 2016 07 07; 11(7):1189-96.
    View in: PubMed
    Score: 0.120
  62. Interleukin-6 Is a Risk Factor for Atrial Fibrillation in Chronic Kidney Disease: Findings from the CRIC Study. PLoS One. 2016; 11(2):e0148189.
    View in: PubMed
    Score: 0.119
  63. Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. J Am Coll Cardiol. 2016 Jan 26; 67(3):239-47.
    View in: PubMed
    Score: 0.119
  64. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med. 2016 06; 129(6):592-599.e1.
    View in: PubMed
    Score: 0.118
  65. Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry. Clin Cardiol. 2016 Feb; 39(2):119-25.
    View in: PubMed
    Score: 0.118
  66. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Am Heart J. 2016 Apr; 174:29-36.
    View in: PubMed
    Score: 0.118
  67. Anticoagulation in atrial fibrillation: impact of mental illness. Am J Manag Care. 2015 Nov 01; 21(11):e609-17.
    View in: PubMed
    Score: 0.117
  68. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015 Jun 30; 65(25):2691-8.
    View in: PubMed
    Score: 0.114
  69. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes. 2015 Jul; 8(4):393-402.
    View in: PubMed
    Score: 0.113
  70. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015 Jul; 170(1):141-8, 148.e1.
    View in: PubMed
    Score: 0.112
  71. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). Am J Cardiol. 2015 Jan 01; 115(1):40-6.
    View in: PubMed
    Score: 0.108
  72. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol. 2014 Aug 15; 114(4):583-6.
    View in: PubMed
    Score: 0.106
  73. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. Am Heart J. 2014 Aug; 168(2):160-7.
    View in: PubMed
    Score: 0.105
  74. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation. 2014 May 20; 129(20):2005-12.
    View in: PubMed
    Score: 0.104
  75. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014 May; 167(5):735-42.e2.
    View in: PubMed
    Score: 0.104
  76. Long-term survival after ischemic stroke in patients with atrial fibrillation. Neurology. 2014 Mar 25; 82(12):1033-7.
    View in: PubMed
    Score: 0.104
  77. Lone atrial fibrillation: does it exist? J Am Coll Cardiol. 2014 May 06; 63(17):1715-23.
    View in: PubMed
    Score: 0.104
  78. Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". Circulation. 2013 Sep 10; 128(11):e172-3.
    View in: PubMed
    Score: 0.101
  79. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013 Aug 13; 128(7):721-8.
    View in: PubMed
    Score: 0.099
  80. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):461-9.
    View in: PubMed
    Score: 0.099
  81. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc. 2013 Feb 01; 2(1):e005694.
    View in: PubMed
    Score: 0.096
  82. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013 Jan 15; 127(2):224-32.
    View in: PubMed
    Score: 0.095
  83. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012 Jul; 43(7):1795-9.
    View in: PubMed
    Score: 0.091
  84. Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm. 2012 Sep; 9(9):1403-8.
    View in: PubMed
    Score: 0.091
  85. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e531S-e575S.
    View in: PubMed
    Score: 0.090
  86. Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. J Am Coll Cardiol. 2012 Jan 10; 59(2):143-9.
    View in: PubMed
    Score: 0.090
  87. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J. 2011 Oct; 162(4):606-612.e1.
    View in: PubMed
    Score: 0.088
  88. Mental illness and warfarin use in atrial fibrillation. Am J Manag Care. 2011 Sep; 17(9):617-24.
    View in: PubMed
    Score: 0.087
  89. American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. Circulation. 2011 Jul 19; 124(3):363-72.
    View in: PubMed
    Score: 0.086
  90. Detection of atrial fibrillation after stroke and the risk of recurrent stroke. J Stroke Cerebrovasc Dis. 2012 Nov; 21(8):726-31.
    View in: PubMed
    Score: 0.085
  91. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011 Jan 04; 154(1):1-11.
    View in: PubMed
    Score: 0.082
  92. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010 Nov; 3(6):624-31.
    View in: PubMed
    Score: 0.082
  93. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010 Jun; 159(6):1102-7.
    View in: PubMed
    Score: 0.080
  94. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation. 2009 Feb 03; 119(4):606-18.
    View in: PubMed
    Score: 0.073
  95. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):546S-592S.
    View in: PubMed
    Score: 0.070
  96. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008 Feb 26; 51(8):810-5.
    View in: PubMed
    Score: 0.068
  97. ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration with the Heart Rhythm Society. J Am Coll Cardiol. 2008 Feb 26; 51(8):865-84.
    View in: PubMed
    Score: 0.068
  98. ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society. Circulation. 2008 Feb 26; 117(8):1101-20.
    View in: PubMed
    Score: 0.068
  99. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007 Aug; 120(8):700-5.
    View in: PubMed
    Score: 0.065
  100. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006 Aug; 54(8):1231-6.
    View in: PubMed
    Score: 0.061
  101. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004 Nov 16; 141(10):745-52.
    View in: PubMed
    Score: 0.055
  102. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):429S-456S.
    View in: PubMed
    Score: 0.054
  103. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Commitee to Develop Data Standards on Atrial Fibrillation). J Am Coll Cardiol. 2004 Jul 21; 44(2):475-95.
    View in: PubMed
    Score: 0.053
  104. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation). Circulation. 2004 Jun 29; 109(25):3223-43.
    View in: PubMed
    Score: 0.053
  105. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003 Sep 11; 349(11):1019-26.
    View in: PubMed
    Score: 0.050
  106. Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. Eur Heart J. 2016 Nov 07; 37(42):3203-3210.
    View in: PubMed
    Score: 0.030
  107. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011 Jul 19; 58(4):395-401.
    View in: PubMed
    Score: 0.022

© 2024 Kaiser Permanente